Paper Sustained Virological Response to Interferon Plus Ribavirin Reduces HIV Progression and Non–Liver-Related Mortality in Patients Coinfected With.

Presentación del tema: "Paper Sustained Virological Response to Interferon Plus Ribavirin Reduces HIV Progression and Non–Liver-Related Mortality in Patients Coinfected With."— Transcripción de la presentación:

1 Paper Sustained Virological Response to Interferon Plus Ribavirin Reduces HIV Progression and Non–Liver-Related Mortality in Patients Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus Juan Berenguer*1, Manel Crespo2, María José Galindo3, María Jesús Téllez4, Carlos Barros5, José María Guardiola6, Rafael Rubio7, Elena Barquilla8, José María Bellón1, Juan González-García9, and Gesida 3603 Study Group 1Hosp. Gen. Univ. Gregorio Marañón~ 2Hosp. Univ. Vall d’Hebrón~ 3Hosp. Clínico Valencia~ 4Hosp. Clínico San Carlos~ 5Hosp. de Móstoles~ 6Hosp. Santa Creu y Sant Pau~ 7Hosp. 12 Octubre~ 8Fundación SEIMC/GESIDA~ and 9Hosp. La Paz Funding sources: Fundación para la Investigación y la Prevención del SIDA en España (FIPSE) (Refs /03 and 36702/07)

2 Background We have previously shown that the achievement of a sustained virological response (SVR) after therapy with interferon plus ribavirin (IFN-RBV) reduces liver-related complications and mortality in HIV/HCV+ patients* Factors Associated with Liver-Related Events by Cox Regression Analysis Factor Adjusted HR 95% CI P Non-SVR versus SVR 8.92 (1.20–66.11) 0.032 F3-F4 vs F0-F2 4.96 (2.27–10.85) 0.000 Geno 1-4 versus 2-3 1.35 (0.63–2.88) 0.443 HCV RNA<500K IU/mL 0.73 (0.33–1.62) 0.444 CDC category C vs A/B 0.95 (0.49–1.87) 0.327 Nadir CD4cells 0.99 (0.99–1.00) 0.319 Liver-related events include: liver-related death, liver decompensation, hepa-tocellular carcinoma, and liver transplantation. 711 HIV/HCV+ patients with and without SVR * Berenguer, J. et al. Hepatology 2009;50: KM curves showing the occurrence of liver-related events

3 Objective To determine the effect of achieving an SVR after anti-HCV therapy on HIV progression and mortality not related to liver disease.

4 Study Design Setting Patients Data Retrieval Follow-up (every 6 mo)
20 clinical centers in Spain Patients HIV/HCV+ patients who started IFN-RBV between Jan 2000 and Jul 2007 Data Retrieval Data were entered into a common database at each institution by means of an ad hoc online application Follow-up (every 6 mo) Survival Liver decompensation HIV-related diseases ART and lab results (CD4+ cells, HIV-VL, HCV-RNA) Liver biopsies, if any In cirrhotics, alpha-fetoprotein (AFP) and ultrasound (US) scan Study duration From the date IFN-RBV was stopped to death or the FU visit Administrative censorship date: 31 April, 2009

5 Sustained Virological Response
SVR was defined as an undetectable serum HCV-RNA level 24 weeks after discontinuation of therapy Patients not fulfilling SVR criteria, including those who relapsed after achieving end of treatment response (ETR), were classified as non-SVR.

6 Endpoints Liver-related complications HIV progression Mortality*
Liver decompensation Ascites, porto-systemic encephalopathy, upper GI bleeding Hepatocellular carcinoma (HCC) Histologically or clinically confirmed (high AFP values and imaging) Liver transplantation HIV progression New AIDS-defining conditions (ADC); 1993 CDC Clinical Classification Mortality* Liver-related death When the train of events that ended in death was caused by liver decompensation or HCC AIDS-related death When death was directly related to one ADC Other causes Non–liver-related and non–AIDS-related * Death reports, autopsy reports (if available), and protocolized formularies were requested. All the information was reviewed by a “mortality committee”, which classified deaths in accordance with the opinion of the attending clinician

7 Patient Characteristics
Patients (N =1428) Male sex-n (%) 1047 (74) Age-yr, median (IQR) 42 (38-45) Prior injection drug use-n (%) 1142 (81) CDC category C-n (%) 310 (22) CD4 cells nadir-n/mm3, median (IQR) 216 ( ) CD4 cells baseline-n/mm3, median (IQR) 528 ( ) HIV RNA 50 copies/mL baseline-n (%) 848 (62) HCV genotype 1-4-n (%) 858 (60) HCV RNA ≥ 500,000 IU/mLmL 931 (65) Advanced fibrosis (F>3 or APRI >2) 429 (30) Alcohol intake >50 g/day-n (%) 69 (5) HAART during HCV treatment-n (%) 1205 (84)

8 Treatment Regimens and SVR
Non-peg IFN + RBV 194 (14) Peg IFN 2b + RBV 549 (38) Peg IFN 2a + RBV 685 (48)

9 Treatment Regimens and SVR
Non-peg IFN + RBV 194 (14) Peg IFN 2b + RBV 549 (38) Peg IFN 2a + RBV 685 (48)

10 Treatment Regimens and SVR
Non-peg IFN + RBV 194 (14) Peg IFN 2b + RBV 549 (38) Peg IFN 2a + RBV 685 (48)

11 Frequency of Events During Follow-up Stratified According to Response to IFN-RBV
Non-SVR (n=908) SVR (n=520) P Follow-up – mo, median (IQR) 48.6 ( ) 41.7 ( ) .002 Lost to follow-up – n (%) 139 (15.3) 50 (9.6) Deaths – n (%) 63 (6.9) 6 (1.2) <.001 Liver-related – n (%) 36 (4.0) 2 (0.4) Non-Liver-related – n (%) 27 (3.0) 4 (0.8) .006 AIDS-related – n (%) 3 (0.3) 0 (0) .189 Other causes – n (%) 24 (2.6) .014 New ADC 34 (3.8) 5 (1.0) New ADC/Non-Liver-related deaths 56 (6.3) 9 (1.7) Liver decompensation – n (%) 84 (9.4) Hepatocellular carcinoma – n (%) 16 (1.8) Liver transplantation – n (%)

12 Frequency of Events During Follow-up Stratified According to Response to IFN-RBV
Non-SVR (n=908) SVR (n=520) P Follow-up – mo, median (IQR) 48.6 ( ) 41.7 ( ) .002 Lost to follow-up – n (%) 139 (15.3) 50 (9.6) Deaths – n (%) 63 (6.9) 6 (1.2) <.001 Liver-related – n (%) 36 (4.0) 2 (0.4) Non-Liver-related – n (%) 27 (3.0) 4 (0.8) .006 AIDS-related – n (%) 3 (0.3) 0 (0) .189 Other causes – n (%) 24 (2.6) .014 New ADC 34 (3.8) 5 (1.0) New ADC/Non-Liver-related deaths 56 (6.3) 9 (1.7) Liver decompensation – n (%) 84 (9.4) Hepatocellular carcinoma – n (%) 16 (1.8) Liver transplantation – n (%)

13 Rate/100 person-years (95% CI)
Incidence Rates of Events During Follow-up Stratified According to Response to IFN-RBV Rate/100 person-years (95% CI) Event Non-SVR (n=908) SVR (n=520) P * Follow-up – mo, median (IQR) 48.6 ( ) 41.7 ( ) .002 Lost to follow-up – n (%) 3.87 ( ) 2.61 ( ) .020 Deaths – n (%) 1.71 ( ) 0.31 ( ) <.001 Liver-related – n (%) 0.98 ( ) 0.1 (-0.04 to 0.25) Non-Liver-related – n (%) 0.73 ( ) 0.21 (0-0.41) .013 AIDS-related – n (%) 0.08 (0-0.17) (0-0.19) .207 Other causes – n (%) 0.65 ( ) .027 New ADC 0.94 ( ) 0.26 ( ) .004 New ADC/Non-Liver-related deaths 1.54 ( ) 0.47 ( ) Liver decompensation – n (%) 2.37 ( ) Hepatocarcinoma – n (%) 0.44 ( ) Liver transplantation – n (%) .003

14 Rate/100 person-years (95% CI)
Incidence Rates of Events During Follow-up Stratified According to Response to IFN-RBV Rate/100 person-years (95% CI) Event Non-SVR (n=908) SVR (n=520) P * Follow-up – mo, median (IQR) 48.6 ( ) 41.7 ( ) .002 Lost to follow-up – n (%) 3.87 ( ) 2.61 ( ) .020 Deaths – n (%) 1.71 ( ) 0.31 ( ) <.001 Liver-related – n (%) 0.98 ( ) 0.1 (-0.04 to 0.25) Non-Liver-related – n (%) 0.73 ( ) 0.21 (0-0.41) .013 AIDS-related – n (%) 0.08 (0-0.17) (0-0.19) .207 Other causes – n (%) 0.65 ( ) .027 New ADC 0.94 ( ) 0.26 ( ) .004 New ADC/Non-Liver-related deaths 1.54 ( ) 0.47 ( ) Liver decompensation – n (%) 2.37 ( ) Hepatocarcinoma – n (%) 0.44 ( ) Liver transplantation – n (%) .003

15 Non–Liver Non-AIDS-Related Deaths
Non-SVR (n=908) SVR (n=520) All non-Liver-Related Deaths 24 4 Bacterial infection 7 - Cardiovascular event 6* 1# Non–AIDS-related malignancy 5 2 Sudden death Traumatic death 1 Suicide * 3 Myocardial infarction, 2 mesenteric ischemia, 1 subarachnoid hemorraghe # Myocardial infarction

16 New AIDS-Related Conditions
Non-SVR (n=908) SVR (n=520) Any 34 5 Recurrent pneumonia 2 PML - Mycobacterium tuberculosis, any site Candidiasis, esophageal 3 Invasive cervical cancer Pneumocystis jiroveci pneumonia Wasting syndrome due to HIV Other (one each) 9 3* *Salmonella septicemia, lymphoma, toxoplasmosis

17 Effect of non-SVR on Risk of New ADC
and Non–Liver-Related Death

18 Effect of non-SVR on Risk of New ADC and Non–Liver-Related Death
*Adjusted for age, sex, prior IDU, HCV genotype, prior ADC, CD4+ nadir, and advanced fibrosis (F3-F4 on liver biopsy or APRI Index > 2)

19 HIV-RNA < 50 copies/mL during FU

20 CD4+ < 200 cells/mL during FU

21 Conclusions Our results suggest that achievement of an SVR after IFN-RBV therapy in HIV/HCV+ patients reduces not only liver-related complications and mortality, but also HIV progression and mortality not related to liver disease. These findings may be associated with a poorer immune response (that does not seem to depend on control of HIV) and/or complications of HCV viremia in patients that did not achieve an SVR.

22 HCV Increases Endothelial Dysfunction in HIV+ Patients Corrected in Responders to IFN-RBV
183 HIV/HCV+ patients on HAART and 24 healthy controls. 32/187 patients underwent therapy with IFN-RBV for 48 wk. HIV/HCV+ patients had higher levels of sICAM-1 and sVCAM-1 than the healthy controls (P<.05). Non SVR patients had increased sICAM-1 and sVCAM-1 serum levels, whereas SVR patients had significantly decreased sICAM-1 levels (P=.003). Fernández de Castro I, et al. CROI Abstract #: Q-143

23 The GESIDA 3603 Team Principal Investigators
J Berenguer, J Gonzalez-García Study Coordinators E Barquilla, H Esteban Statistician JM Bellón H. Gregorio Marañón, Madrid JM Bellón, J Cosín, I Gutiérrez, JC López, P Miralles, B Padilla, M Ramírez, M Sánchez-Conde, J Berenguer, H. 12 de Octubre, Madrid MA Hernando, F Pulido, V Rodríguez, R Rubio H. Clinic, Barcelona P Callau, JM Gatel, J Mallolas, JM Miro H. Clínico Univ de Valencia, Valencia A Ferrer, MJ Galindo H. Clínico San Carlos, Madrid MJ Téllez, J Vergas H. Donostia, San Sebastián J Arrizabalaga, JA Iribarren, MA Von Wichmann H. General de Valencia, Valencia E Ortega, L Ortiz H. La Paz, Madrid J Alvarez, JR Arribas, I Bernardino, M Mora, F Pascual, JM Peña, E Rodríguez, I Pérez-Valero, F Zamora, J González-García, H. Germans Trias i Pujol, Badalona B Clotet, A Jou, C Tural H. Getafe, Madrid G Gaspar, G Pérez H. Guadalajara, Guadalajara M Rodríguez, ML Montes H. La Fe, Valencia S Cuellar, J López-Aldeguer H. La Princesa, Madrid I Santos, J Sanz H. Móstoles, Madrid C Barros, E Condés Fundación SEIMC-GESIDA, Madrid E Aznar, E Barquilla, H Esteban, B Moyano H. Príncipe de Asturias, Madrid A Arranz, J de Miguel, J Sanz H. Ramón y Cajal, Madrid A Moreno, S Moreno, C Quereda, MA Sanfrutos H. Santa Creu i Sant Pau, Barcelona P Domingo, JM Guardiola H. Severo Ochoa, Madrid M Cervero, JJ Jusdado, R Torre H. Vall d´Hebron, Barcelona M Crespo, E Van den Eynde